Randox Laboratories Limited

Other

Philip Andrew Lowry

Elouard Benchikh

Ivan Robert McConnell

Peter Fitzgerald

Stephen Peter Fitzgerald

Paul John Innocenzi

Robert Ivan McConnell

Alex Chacko

Elouard Benchik

Antibodies, immunoassay methods and kits for the detection and determination of 3,4,-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide and 3,4,-dichloro-N-[2-(methylamino)cyclohexyl]-N-methylbenzamide, as well as the precursory immunogens, are described.

U-47700 immunoassay

Immunoassay methods and their requisite components for the detection and determination of phenethylamines of the 2C and DO sub-families are described.

Immunoassay for phenethylamines of the 2C and DO sub-families

The present invention relates to antibodies for use in detecting polymyxins and tracers; and to a single-capture immunodetection method and kits, each utilising the antibodies of the invention, and disclosed tracers.

Detection of polymyxins

An immunoassay method for detecting and determining adamantane substituted indazole and indole synthetic cannabinoids is described. Also described are components for use in implementing the method, namely, antibodies, detection agents, solid state devices and kits as well as immunogens used to raise the antibodies.

Immunoassay for synthetic cannabinoids of the adamantyl indazole/indole-3-carboxamide family

Antibodies, immunoassay methods and kits for the detection and determination of 3,4-dichloro-N-[(1-(dimethylamino)cyclohexyl)methyl]benzamide and 3,4-dichloro-N-[(1-(methylamino)cyclohexyl)methyl]benzamide, as well as the precursory immunogens, are described.

AH-7921 Detection

Components for enabling immunodection of indazole synthetic cannabinoids are described including immunogens, haptens, antibodies, methods and kits.

Detection of indazole synthetic cannabinoids

An immunoassay method is described which detects O-desmethyltramadol only. This enables an assay of high sensitivity and specificity avoiding false positive results. The unique antibodies incorporated in the immunoassay method can be combined with antibodies which detect mitragynine to provide an assay which increases the possibility of detecting the commonly found drug combination of O-desmethyltramadol and mitragynine.

Opioid detection

Components for enabling immunodetection of methoxetamine are described including immunogens, haptens, antibodies and kits.

Assay for methoxetamine

The current invention describes novel immunogens which are used in the production of novel antibodies with unique binding properties in that they cross-react with a variety of phenylpiperazine derivatives. These antibodies enable methods and kits to detect and/or determine phenylpiperazine derivatives (for example mCPP, TFMPP and MeOPP) in an in vitro sample which are advantageous over currently available analytical methods in terms of cost, ease of use, speed and sensitivity.

Assay for the detection of the phenylpiperazine family

The invention describes methods and kits for detecting and determining current and future synthetic cannabinoids from the JWH and CP families. Unique antibodies derived from novel immunogens enable said methods and kits.

Detection of synthetic cannabinoids

The invention relates to the field of drug detection and describes antibody-based components methods and kits for the detection and quantification of alkaloids of the plant kratom. The invention is underpinned by novel antibodies which specifically bind to mitragynine alkaloids found in the kratom plant and their metabolites.

Immunoassay for detecting kratom, its constituents and their use

The invention provides novel haptens and immunogens for the preparation of novel monoclonal antibodies, which detect the synthetic opioid meperidine and its active metabolite normeperidine. These antibodies enable methods and kits, which are useful in an immunoassay for therapeutic drug monitoring (TDM) and in extending the window of detection for cases of abuse and drug-facilitated sexual assault (DFSA).

Immunoassays for meperidine and metabolites

The invention describes antibodies that bind venlafaxine and O-desmethylvenlafaxine. The antibodies are derived from novel haptens and immunogens and are used in methods and kits to detect and quantify venlafaxine and O-desmethylvenlafaxine. The invention also describes novel detecting agents which can be used in the methods and kits of the invention.

Venlafaxine assay

The current invention provides an improved immunoassay for the detection and determination of pyrrolidinophenone based designer drugs in hair and biological fluids (urine, blood, and oral fluid). The generic immunoassay is underpinned by novel, sub-family-specific antibodies, which display surprising sensitivity. The invention further describes substrates comprising an antibody that is specific to compounds of the pyrrolidinophenone family. Also described are the novel immunogens from which the antibodies are derived and kits incorporating the antibodies of the current invention.

Growing community of inventors

Crumlin Antrim, United Kingdom

Philip Andrew Lowry